11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy
LH Mammatas, M Yaqub, NH Hendrikse… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to
potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study …
potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study …
[PDF][PDF] Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk MW Verheul, Adriaan A …
LH Mammatas, M Yaqub, N Harry - PET imaging of targets and …, 2021 - research.vu.nl
Purpose: Sorafenib leads to clinical benefit in a subgroup of patients, while all are exposed
to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this …
to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this …
[HTML][HTML] Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma
Z Li, K Herrmann, S Pirsig… - American Journal of …, 2014 - ncbi.nlm.nih.gov
The role of [18 F] fluorodeoxyglucose ([18 F] FDG) PET in staging of sarcoma is well
established. The aim of this preclinical study was to compare [18 F] fluorothymidine ([18 F] …
established. The aim of this preclinical study was to compare [18 F] fluorothymidine ([18 F] …
Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion‐weighted MRI, choline spectroscopy and 18F …
O Karroum, L Mignion, J Kengen… - Contrast media & …, 2013 - Wiley Online Library
The purpose of this study was to determine the value of different imaging modalities, that is,
magnetic resonance imaging/spectroscopy (MRI/MRS) and positron emission tomography …
magnetic resonance imaging/spectroscopy (MRI/MRS) and positron emission tomography …
Does Sorafenib Fit for All?
P Lucatelli, R Argirò, L Saba, GB Levi Sandri - Radiology, 2017 - pubs.rsna.org
LETTERS TO THE EDITOR 920 radiology. rsna. org n Radiology: Volume 284: Number 3—
September 2017 colleagues retrospectively analyzed patients treated with transarterial …
September 2017 colleagues retrospectively analyzed patients treated with transarterial …
Correlation of sorafenib plasma concentrations and clinical toxicity: a prospective population pharmacodynamic and pharmacokinetic study
B Billemont, M Hornecker, S Ropert… - Journal of Clinical …, 2009 - ascopubs.org
e14585 Background: Sorafenib is an angiogenesis inhibitor recently approved for the
treatment of metastatic renal cell carcinoma and hepatocarcinoma. This oral multi-targeted …
treatment of metastatic renal cell carcinoma and hepatocarcinoma. This oral multi-targeted …
A pharmacokinetic (PK) and safety study of sorafenib plus capecitabine in advanced solid tumors
CE McKay, J Infante, S Jones, J Bendell… - Journal of Clinical …, 2009 - ascopubs.org
e14548 Background: The addition of a multi-targeted kinase inhibitor such as sorafenib (S)
to standard chemotherapy holds promise for improving therapeutic efficacy in multiple …
to standard chemotherapy holds promise for improving therapeutic efficacy in multiple …
[HTML][HTML] [11C] Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer
AJ Poot, B van der Wildt, M Stigter-van Walsum… - Nuclear Medicine and …, 2013 - Elsevier
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) like sorafenib are important anticancer
therapeutics with thus far limited treatment response rates in cancer patients. Positron …
therapeutics with thus far limited treatment response rates in cancer patients. Positron …
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment
O Maksimovic, C Schraml… - American Journal of …, 2010 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to illustrate the characteristic changes induced in
different tumor types by the multitargeted tyrosine kinase inhibitor sorafenib. CONCLUSION …
different tumor types by the multitargeted tyrosine kinase inhibitor sorafenib. CONCLUSION …
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
B Blanchet, B Billemont, J Cramard… - … of pharmaceutical and …, 2009 - Elsevier
Sorafenib, a new oral multikinase inhibitor with antiangiogenic properties, has demonstrated
preclinical and clinical activity against several tumor types. The aims of this study were to …
preclinical and clinical activity against several tumor types. The aims of this study were to …